The company has reported a net loss of $10.91 million, or $1.37 per share, for the six months ended June 30, 2009, compared to a net loss of $16.1 million, or $2.20 per share, for the same period of 2008.
Technology licensing fee revenue was $5,000 for the second quarter of 2009, compared to $13,000 for the same period of 2008. For the six months ended June 30, 2009, technology licensing fee revenue was $10,000 compared to $27,000 for the same period of 2008.
Alan Kessman, CEO of Vion, said: "This is an exciting time for our company. We are preparing for the Oncologic Drugs Advisory Committee meeting at the beginning of September 2009 and looking forward to presenting our data to the committee in support of Onrigin for its use as a new therapeutic agent for elderly poor-risk acute myeloid leukemia patients."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index